MedMira Resumes Sales to the Middle East

Instant HIV Tests Destined for UAE as Demand Increases for Immigration

and Emergency Care

Mar 21, 2006, 00:00 ET from MedMira Inc.

    HALIFAX, March 21 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
 Venture: MIR, NASDAQ:   MMIRF) the global market leader in premium rapid
 diagnostic solutions, announced today that it has received an order for 10,000
 MiraWell(R) Rapid HIV Tests (MiraWell(R) HIV) from its Middle East
 distributor, Spree Trading, a member of the Shawwa Group International, which
 is a multibillion-dollar global corporation with healthcare and diagnostic
 sales divisions. These tests are destined for the Dubai market in the United
 Arab Emirates (UAE), where they will be sold to immigration services,
 hospitals and other healthcare facilities providing rapid HIV testing.
     "We believe the UAE market and the Middle East region generally hold a
 great deal of potential for the sale of MedMira's products," said Stephen
 Sham, chairman and CEO, MedMira. "Spree Trading's aggressive marketing plans
 and healthcare experience are key to capitalizing on sales of our products in
 this growing market."
     In 2005, MedMira completed the registration process with the UAE Ministry
 of Health. Spree Trading will be pursuing further product evaluations, tender
 opportunities, and new sales channels for MedMira's full product line. MedMira
 will work closely with Spree Trading to evaluate and seek new market
 opportunities for other MedMira products including an over-the-counter (OTC)
 rapid HIV test and rapid test for HIV/Hepatitis C (HCV) co-infections.
     Sham continued, "The sophisticated healthcare system in the UAE will
 enable MedMira to expand our product offering in the region to include OTC
 tests and other, more advanced rapid diagnostic solutions."
     MiraWell(R) HIV is the fastest flow-through rapid HIV test in the world,
 providing results instantly. MedMira's rapid tests have a wide range of
 applications including occupational exposures, labor & delivery and general
 screening. When used for general screening purposes, rapid HIV tests can
 provide significant value, especially in a market such as Dubai where
 expatriates make up 80% of the population and must be tested for HIV every two
 years as part of the visa renewal process.
     About MedMira
     MedMira is the leading global manufacturer and marketer of in vitro flow-
 through rapid diagnostic tests. MedMira's tests provide reliable, rapid
 diagnosis in just 3 minutes for the detection of human antibodies in human
 serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
 United States FDA and the SFDA in the People's Republic of China have approved
 MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
     MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
 in clinical laboratories, hospitals, and clinics where professional
 counselling and patient treatment are immediately available.
     The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
 (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
 Regions, in the People's Republic of China. MiraCare(TM) is sold through
 MedMira's distributor network to pharmacies, hospitals and laboratories in the
 European Union.
     MedMira delivers rapid diagnostic solutions to healthcare communities
 around the globe. Its corporate offices and manufacturing facilities are
 located in Halifax, Nova Scotia, Canada with a representative office in
 Guilin, China.
     This news release contains forward-looking statements, which involve risk
 and uncertainties and reflect the company's current expectation regarding
 future events. Actual events could materially differ from those projected
 herein and depend on a number of factors including, but not limited to,
 changing market conditions, successful and timely completion of clinical
 studies, uncertainties related to the regulatory approval process,
 establishment of corporate alliances and other risks detailed from time to
 time in the company quarterly filings.
     The TSX Venture Exchange has not reviewed and does not accept
     responsibility for the adequacy or accuracy of this statement.
     For more information visit MedMira's website at

SOURCE MedMira Inc.